Top Markets
#1 Celer Network Celer Network +49.10%
#2 Gravity Gravity +24.44%
#3 Galxe Galxe +23.88%
#4 ICON ICON +13.39%
#5 MemeCore MemeCore +13.25%
#6 Cartesi Cartesi +12.87%
#7 Zilliqa Zilliqa +10.95%
#8 Genius Genius +10.65%
#9 Ontology Gas Ontology Gas +9.33%
#10 CyberDEX CyberDEX +7.13%
Coin of the day
Celer Network Celer Network
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rang in Aktien #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Aktienkurs
$0.1559364
Zuletzt synchronisiert: 2026-09-18
Marktkapitalisierung
$195.17K
Veränderung (1 Tag)
6.60%
Veränderung (1 Jahr)
-30.91%
Land
GB
Handel Fusion Antibodies plc (FAB)

Kategorie

Healthcare
P/B-Verhältnis für Fusion Antibodies plc (FAB)
P/B-Verhältnis zum September 2026 TTM: 14.42
Laut den neuesten Finanzberichten und dem Aktienkurs von Fusion Antibodies plc beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 14.42. Am Ende des Jahres 2024 lag das P/B-Verhältnis bei 1.19.
P/B-Verlauf für Fusion Antibodies plc von 2013 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
2026 (TTM) 14.42 63.73%
2025 8.81 638.88%
2024 1.19 -86.62%
2023 8.92 111.06%
2022 4.23 -49.81%
2021 8.42 93.06%
2020 4.36 270.89%
2019 1.18 -54.53%
2018 2.59 -83.83%
2017 15.99 -14.59%
2016 18.73 -88.38%
2015 161.16 -102.17%
2014 -7.41K -918.70%
2013 905.56 0.00%
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.5144 -54.84%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.3983 -48.71%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 8.5918 -40.43%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 3.9974 -72.29%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH